CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
ATE455785T1
(de)
|
2000-11-02 |
2010-02-15 |
Ajinomoto Kk |
Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
|
EP1344780A4
(en)
*
|
2000-11-30 |
2004-01-28 |
Kissei Pharmaceutical |
GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
|
HU228915B1
(en)
|
2000-12-28 |
2013-06-28 |
Kissei Pharmaceutical |
Glucopyranosyloxypyrazole derivatives and use thereof
|
DE60230591D1
(de)
|
2001-02-26 |
2009-02-12 |
Kissei Pharmaceutical |
Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
|
JP4147111B2
(ja)
|
2001-02-27 |
2008-09-10 |
キッセイ薬品工業株式会社 |
グルコピラノシルオキシピラゾール誘導体およびその医薬用途
|
JP4590159B2
(ja)
|
2001-04-04 |
2010-12-01 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
グルコース再吸収阻害剤およびpparモジュレーターを含んで成る併用療法
|
ATE442148T1
(de)
|
2001-04-04 |
2009-09-15 |
Ortho Mcneil Janssen Pharm |
Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
|
JP4292570B2
(ja)
|
2001-04-27 |
2009-07-08 |
味の素株式会社 |
N−置換ピラゾール−o−グリコシド誘導体及びそれらを含有する糖尿病治療薬
|
CA2448741C
(en)
|
2001-05-30 |
2010-06-22 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
|
WO2003020737A1
(en)
*
|
2001-09-05 |
2003-03-13 |
Bristol-Myers Squibb Company |
O-pyrazole glucoside sglt2 inhibitors and method of use
|
US7956041B2
(en)
|
2002-04-26 |
2011-06-07 |
Ajinomoto Co., Inc. |
Prophylactic and therapeutic agent of diabetes mellitus
|
AR040588A1
(es)
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
JP2006501205A
(ja)
*
|
2002-07-30 |
2006-01-12 |
カリキオン インコーポレイテッド |
エゼチミブ組成物、並びにコレステロールに関連した良性および悪性の腫瘍を治療する方法
|
CN100351263C
(zh)
*
|
2002-08-08 |
2007-11-28 |
橘生药品工业株式会社 |
吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
|
MXPA05001549A
(es)
*
|
2002-08-08 |
2005-05-05 |
Kissei Pharmaceutical |
Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion.
|
CA2478889A1
(en)
|
2002-08-09 |
2004-02-19 |
Taisho Pharmaceutical Co., Ltd. |
Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
|
JP2004137245A
(ja)
*
|
2002-08-23 |
2004-05-13 |
Kissei Pharmaceut Co Ltd |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
CN100413878C
(zh)
*
|
2002-08-23 |
2008-08-27 |
橘生药品工业株式会社 |
吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
|
WO2004019958A1
(ja)
*
|
2002-08-27 |
2004-03-11 |
Kissei Pharmaceutical Co., Ltd. |
ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
|
WO2004019926A1
(ja)
*
|
2002-08-30 |
2004-03-11 |
Mitsubishi Pharma Corporation |
心不全の予防及び/又は治療剤
|
AU2003272903A1
(en)
*
|
2002-10-04 |
2004-04-23 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
|
CN1744916A
(zh)
*
|
2002-12-04 |
2006-03-08 |
橘生药品工业株式会社 |
预防和治疗高血糖所导致的疾病
|
EP1577317A4
(en)
*
|
2002-12-25 |
2007-05-09 |
Kissei Pharmaceutical |
NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, MEDICINAL COMPOSITIONS COMPRISING SAID DERIVATIVES AND MEDICAL USE OF SAID DERIVATIVES
|
ATE490788T1
(de)
|
2003-04-25 |
2010-12-15 |
Gilead Sciences Inc |
Antivirale phosphonate analoge
|
EP1637539B1
(en)
*
|
2003-06-20 |
2012-01-18 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, drug composition containing the same and production intermediate therefor
|
BRPI0413232B8
(pt)
|
2003-08-01 |
2021-05-25 |
Mitsubishi Tanabe Pharma Corp |
composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
UA86042C2
(en)
|
2003-08-01 |
2009-03-25 |
Янссен Фармацевтика Н.В. |
Substituted indazole-o-glucosides
|
DE502004008951D1
(de)
*
|
2003-08-26 |
2009-03-19 |
Boehringer Ingelheim Pharma |
Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
WO2005021039A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Cotherix, Inc. |
Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
|
US7803838B2
(en)
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
PL1750862T3
(pl)
|
2004-06-04 |
2011-06-30 |
Teva Pharma |
Kompozycja farmaceutyczna zawierająca irbesartan
|
US7838552B2
(en)
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
JP5010918B2
(ja)
*
|
2004-07-21 |
2012-08-29 |
キッセイ薬品工業株式会社 |
肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
EP1778251B1
(en)
|
2004-07-27 |
2011-04-13 |
Gilead Sciences, Inc. |
Nucleoside phosphonate conjugates as anti hiv agents
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
WO2006034435A2
(en)
*
|
2004-09-21 |
2006-03-30 |
Point Therapeutics, Inc. |
Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
MY147375A
(en)
|
2005-01-31 |
2012-11-30 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
EP1864993B1
(en)
*
|
2005-03-17 |
2012-05-16 |
Kissei Pharmaceutical Co., Ltd. |
Process for production of glucopyranosyloxypyrazole derivative
|
AR054852A1
(es)
*
|
2005-07-22 |
2007-07-18 |
Boehringer Ingelheim Int |
Procesos para preparar derivados de pirazol 0- glucosido y nuevos intermediarios de dichos procesos
|
UY29694A1
(es)
*
|
2005-07-28 |
2007-02-28 |
Boehringer Ingelheim Int |
Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
|
KR100982088B1
(ko)
*
|
2005-08-31 |
2010-09-13 |
에프. 호프만-라 로슈 아게 |
11베타-hsd1 억제제로서의 피라졸론 유도체
|
UY30082A1
(es)
|
2006-01-11 |
2007-08-31 |
Boehringer Ingelheim Int |
Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
|
CN100384416C
(zh)
*
|
2006-03-20 |
2008-04-30 |
杨军 |
一种用于治疗心血管疾病的药物组合物
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
TWI418556B
(zh)
*
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
TWI499414B
(zh)
*
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
NZ577391A
(en)
*
|
2006-12-04 |
2011-11-25 |
Janssen Pharmaceutica Nv |
Thienyl-containing glycopyranosyl derivatives as antidiabetics
|
JP5330260B2
(ja)
|
2006-12-06 |
2013-10-30 |
スミスクライン ビーチャム コーポレーション |
二環式化合物ならびに抗糖尿病薬としての使用
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
JP5596545B2
(ja)
|
2007-09-10 |
2014-09-24 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Sgltの阻害物質として有用な化合物の製造方法
|
US8399418B2
(en)
*
|
2007-12-27 |
2013-03-19 |
Kissei Pharmaceutical Co., Ltd. |
Monosebacate of pyrazole derivative
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
AU2009268681B2
(en)
|
2008-07-08 |
2014-10-02 |
Gilead Sciences, Inc. |
Salts of HIV inhibitor compounds
|
RS52236B
(en)
*
|
2008-08-28 |
2012-10-31 |
Pfizer Inc. |
DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
|
US20100113603A1
(en)
*
|
2008-10-16 |
2010-05-06 |
Aronne Louis J |
Combination therapies for the treatment of obesity
|
WO2010045522A2
(en)
*
|
2008-10-16 |
2010-04-22 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
WO2010045416A2
(en)
*
|
2008-10-16 |
2010-04-22 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
US20100113581A1
(en)
*
|
2008-10-16 |
2010-05-06 |
Aronne Louis J |
Combination therapies for the treatment of obesity
|
US20100113604A1
(en)
*
|
2008-10-16 |
2010-05-06 |
Aronne Louis J |
Combination therapies for the treatment of obesity
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
US20100167989A1
(en)
*
|
2008-10-23 |
2010-07-01 |
Auspex Pharmaceuticals, Inc. |
Isopropoxyphenylmethyl inhibitors of sglt2
|
EP2395983B1
(en)
|
2009-02-13 |
2020-04-08 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
WO2010118384A2
(en)
*
|
2009-04-10 |
2010-10-14 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist compounds for estrogen-deficient mammals
|
WO2010127067A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Glaxosmithkline Llc |
Chemical process
|
US20100331419A1
(en)
*
|
2009-06-25 |
2010-12-30 |
Aronne Louis J |
Combination Therapies for the Treatment of Obesity
|
WO2010151565A2
(en)
*
|
2009-06-26 |
2010-12-29 |
Metabolous Pharmaceuticals, Inc. |
Combination therapies for the treatment of obesity
|
US20100331999A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Aronne Louis J |
Combination Therapies for the Treatment of Obesity
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
EP2451797B1
(en)
|
2009-07-10 |
2013-04-03 |
Janssen Pharmaceutica, N.V. |
CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
|
US20110015663A1
(en)
*
|
2009-07-17 |
2011-01-20 |
Aronne Louis J |
Combination Therapies for the Treatment of Obesity
|
US20110082407A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Aronne Louis J |
Combination Therapies for the Treatment of Obesity
|
US9174971B2
(en)
|
2009-10-14 |
2015-11-03 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of SGLT2
|
DK2496583T3
(en)
|
2009-11-02 |
2015-02-02 |
Pfizer |
Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
|
KR20130028058A
(ko)
*
|
2010-02-03 |
2013-03-18 |
엠이에이치 어소시에이츠, 인코포레이티드 |
선택적 및 생활성 동배체로서의 다수 치환된 플루오로메탄류
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US20140088027A1
(en)
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
KR101931209B1
(ko)
|
2010-05-11 |
2018-12-20 |
얀센 파마슈티카 엔.브이. |
Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
|
EP2590634B1
(en)
|
2010-07-09 |
2016-03-09 |
BHV Pharma, Inc. |
Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CA2851717A1
(en)
*
|
2011-01-10 |
2013-07-25 |
Muhammed Majeed |
Anti-obesity potential of calebin a
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
AU2012241897C1
(en)
|
2011-04-13 |
2017-05-11 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of SGLT2
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
|
MX2013014135A
(es)
|
2011-06-03 |
2014-01-23 |
Boehringer Ingelheim Int |
Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
|
RU2500407C2
(ru)
*
|
2012-02-20 |
2013-12-10 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации |
Средство, обладающее мочегонным действием
|
RU2517091C2
(ru)
*
|
2012-02-20 |
2014-05-27 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации) |
Средство, обладающее мочегонным действием
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
DK2981269T3
(da)
|
2013-04-04 |
2023-10-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Behandling af stofskifteforstyrrelser hos hestedyr
|
KR20240017116A
(ko)
|
2013-12-17 |
2024-02-06 |
베링거잉겔하임베트메디카게엠베하 |
고양이과 동물에서 대사 장애의 치료
|
RU2643003C1
(ru)
|
2013-12-26 |
2018-01-29 |
Поско |
Устройство и способ непрерывного литья и прокатки стального листа
|
ES2951127T3
(es)
|
2014-01-23 |
2023-10-18 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales caninos
|
US10688116B2
(en)
|
2014-04-01 |
2020-06-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
KR200484486Y1
(ko)
*
|
2016-05-09 |
2017-09-12 |
연세대학교 원주산학협력단 |
시료채취장치
|
AU2017344882A1
(en)
|
2016-10-19 |
2019-03-28 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
|
EP3960740B1
(en)
|
2017-08-01 |
2023-11-15 |
Gilead Sciences, Inc. |
Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
|
US20210169881A1
(en)
|
2017-11-30 |
2021-06-10 |
Idorsia Pharmaceuticals Ltd |
Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
|
WO2019193572A1
(en)
*
|
2018-04-05 |
2019-10-10 |
Glenmark Pharmaceuticals Limited |
An improved process for the preparation remogliflozin etabonate or pharmaceutically acceptable salt, solvate, hydrate thereof
|
WO2019201752A1
(en)
|
2018-04-17 |
2019-10-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
US11759474B2
(en)
|
2019-11-28 |
2023-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors in the drying-off of non-human mammals
|
CA3167531A1
(en)
|
2020-02-17 |
2021-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
KR20240040106A
(ko)
|
2021-07-28 |
2024-03-27 |
베링거잉겔하임베트메디카게엠베하 |
비-사람 포유류에서 신장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
|
CN117715640A
(zh)
|
2021-07-28 |
2024-03-15 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途
|
WO2023006745A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
WO2023129595A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Obicetrapib and sglt2 inhibitor combination
|
WO2023227492A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|